Definium Therapeutics (NASDAQ: DFTX) grows cash to $1.1B, Q2 loss deepens

Rhea-AI Filing Summary

Definium Therapeutics, Inc. reported second-quarter 2026 results alongside major clinical milestones. The Phase 3 Emerge trial in major depressive disorder randomized 149 participants 1:1 to DT120 ODT 100 µg or placebo and met its primary and all key secondary endpoints, showing an 8.1-point placebo-adjusted improvement in MADRS total score at Week 6 (Cohen’s d = 0.83; p<0.0001) and a 7.3-point improvement at Week 12. DT120 ODT was generally well tolerated, with no serious adverse events or suicidality signal observed.

The company completed enrollment in the Phase 3 Voyage and Panorama GAD studies, with topline data expected in August and September 2026, initiated the Phase 3 Ascend MDD study, and plans to start the Haven PTSD study in 2027. Definium completed an underwritten public offering of 23,676,471 common shares for gross proceeds of $805 million and net proceeds of approximately $757.9 million, ending June 30, 2026 with about $1.1 billion in cash, cash equivalents and investments versus $411.6 million at December 31, 2025. R&D expenses rose to $48.7 million and G&A to $26.4 million for the quarter. Net loss was $159.0 million, compared with $42.7 million a year earlier, largely reflecting an $86.2 million non-cash increase in the fair value of warrant liabilities; the company states its cash resources are expected to fund operations into 2030.

Positive

• Phase 3 Emerge trial met primary and key secondary endpoints in major depressive disorder, with an 8.1-point placebo-adjusted MADRS improvement at Week 6 and favorable tolerability, supporting DT120 ODT’s reported efficacy profile.
• Cash, cash equivalents and investments increased to about $1.1 billion as of June 30, 2026, including net proceeds of approximately $757.9 million from a public equity offering, and the company states this should fund operations into 2030.

Negative

• Quarterly net loss widened to $159.0 million from $42.7 million a year earlier, driven largely by an $86.2 million non-cash increase in warrant liabilities and higher R&D and G&A spending.

Filing Explained

As of June 30, 2026, Definium had 134,365,950 common shares issued and outstanding, up from 98,776,265 on December 31, 2025; the larger share base means each existing holder represents a smaller percentage of the company absent offsetting changes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Cash, cash equivalents and investments: $1.1 billion Underwritten public offering gross proceeds: $805 million R&D expenses Q2 2026: $48.7 million +4 more

7 metrics

Cash, cash equivalents and investments $1.1 billion As of June 30, 2026, versus $411.6 million as of December 31, 2025

Underwritten public offering gross proceeds $805 million 23,676,471 common shares sold in an underwritten public offering

R&D expenses Q2 2026 $48.7 million Three months ended June 30, 2026, versus $29.8 million in Q2 2025

G&A expenses Q2 2026 $26.4 million Three months ended June 30, 2026, versus $11.1 million in Q2 2025

Net loss Q2 2026 $159.0 million Three months ended June 30, 2026, versus $42.7 million in Q2 2025

Non-cash increase in warrant liabilities $86.2 million Change in fair value of 2022 USD Financing Warrants in Q2 2026

Common shares outstanding 134,365,950 shares Issued and outstanding as of June 30, 2026

Key Terms

Montgomery-Åsberg Depression Rating Scale (MADRS), Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), orally disintegrating tablet (ODT), 2022 USD Financing Warrants, +1 more

5 terms

Montgomery-Åsberg Depression Rating Scale (MADRS) medical

"placebo-adjusted improvement of 8.1 points in Montgomery-Åsberg Depression Rating Scale (MADRS)"

A 10-question clinician-rated scale that measures the severity of depressive symptoms and tracks changes over time, often used in clinical trials as a standardized “thermometer” for depression. Investors watch MADRS results because improvements or lack of change can drive trial success, regulatory decisions and ultimately a drug’s commercial prospects, much like an exam score signals whether a new product meets expectations.

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) medical

"primary endpoint in the study is expected to be the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)"

A structured interview conducted by a trained clinician that measures the presence and severity of post-traumatic stress disorder symptoms as defined by the DSM-5. It serves as a standardized “ruler” to track symptom changes in clinical care and trials, so investors pay attention because results tied to this scale often drive regulatory decisions, label claims, trial success and market value for therapies targeting PTSD.

orally disintegrating tablet (ODT) medical

"DT120 ODT (lysergide tartrate) is an ergoline derivative and orally disintegrating tablet (ODT)"

2022 USD Financing Warrants financial

"Change in fair value of 2022 USD Financing Warrants"

Schedule I controlled substances regulatory

"reschedule any of our product candidates, if approved, containing Schedule I controlled substances"

Earnings Snapshot

Net loss: $159.0 million · Guidance included

Three months ended June 30, 2026

Net loss $159.0 million Compared with a $42.7 million net loss in the three months ended June 30, 2025

Research and development expense $48.7 million Compared with $29.8 million in the prior-year quarter

General and administrative expense $26.4 million Compared with $11.1 million in the prior-year quarter

Cash, cash equivalents and investments Approximately $1.1 billion As of June 30, 2026, versus $411.6 million as of December 31, 2025

Guidance

The company states that based on its current operating plan and anticipated milestones, its cash, cash equivalents and investments as of June 30, 2026 will be sufficient to fund operations into 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/06/2026 - 04:11 PM Accepted by SEC EDGAR 08/06/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What were Definium Therapeutics (DFTX) key financial results for Q2 2026?

Definium reported a Q2 2026 net loss of $159.0 million, versus $42.7 million a year earlier. R&D expenses were $48.7 million and G&A expenses $26.4 million, reflecting expanded clinical programs and corporate infrastructure.

How much cash does Definium Therapeutics (DFTX) have, and what is its runway?

As of June 30, 2026, Definium held about $1.1 billion in cash, cash equivalents and investments, up from $411.6 million. The company states this balance is expected to fund operations under its current plan into 2030.

What were the Phase 3 Emerge study results for Definium Therapeutics (DFTX) DT120 ODT in MDD?

The Phase 3 Emerge trial met its primary and key secondary endpoints in MDD. DT120 ODT achieved an 8.1-point placebo-adjusted MADRS improvement at Week 6 and 7.3 points at Week 12, with no serious adverse events or suicidality signal reported.

What is the status of Definium Therapeutics (DFTX) Phase 3 GAD and MDD programs?

Definium has completed enrollment in the Phase 3 Voyage and Panorama GAD studies, with topline data expected August and September 2026. The Phase 3 Ascend MDD study has begun enrollment, with topline data expected in 2027, and the Haven PTSD study is planned for 2027.

What equity financing did Definium Therapeutics (DFTX) complete in Q2 2026?

Definium completed an underwritten public offering of 23,676,471 common shares, generating $805 million in gross proceeds and approximately $757.9 million in net proceeds after underwriting discounts, commissions and expenses.

What drove the increase in Definium Therapeutics (DFTX) net loss in Q2 2026?

The larger $159.0 million net loss was mainly due to an $86.2 million non-cash increase in the fair value of 2022 USD Financing Warrants, along with higher R&D and G&A expenses supporting DT120 and broader pipeline activities.

false000181381400018138142026-08-062026-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 06, 2026

Definium Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia			001-40360	98-1582438
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
One World Trade Center Suite 8500
New York, New York				10007
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (212) 220-6633

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		DFTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended June 30, 2026, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information contained in this Item 2.02 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 6, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			DEFINIUM THERAPEUTICS, INC.
Date:	August 6, 2026	By:	/s/ Robert Barrow
			Name: Robert Barrow Title: Chief Executive Officer

Exhibit 99.1

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robust, and durable efficacy

Topline results from Phase 3 GAD studies of DT120 ODT in generalized anxiety disorder (GAD) on track: Voyage results anticipated week of August 10; Panorama results anticipated September 2026

Approximately $1.1 billion in cash, cash equivalents, and investments as of June 30, 2026

Conference call scheduled today at 4:30 p.m. EDT

NEW YORK, August 6, 2026 -- Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended June 30, 2026, and recent highlights.

“The second quarter marked a meaningful inflection point for Definium as we further established our leadership position in psychedelic medicine,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “The unprecedented Phase 3 Emerge results validated the highly differentiated profile of DT120 ODT and reinforced its potential to become a best-in-class treatment across multiple psychiatric disorders. We also continued to execute across our pipeline, completing enrollment in Voyage and Panorama and initiating enrollment in Ascend. Our public offering generated approximately $805 million in gross proceeds and provides the capital to advance our clinical and commercial strategy from a position of strength. We believe Definium is uniquely positioned to advance a potential new treatment paradigm across some of the field’s largest and most underserved indications.”

Business Updates

▪Completed an underwritten public offering of 23,676,471 common shares of the Company for gross proceeds of $805 million. Net proceeds from the offering were approximately $757.9 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

▪Launched Wired for Worry, a new healthcare provider disease education platform designed to deepen understanding of GAD, reinforce the importance of ongoing assessment, and help healthcare professionals better understand the neurobiological mechanisms that may contribute to the disorder.

1

Program Status and Anticipated Milestones

▪Announced positive topline results from Phase 3 Emerge study (MDD) with 149 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo. Key findings included:

oMet the primary endpoint and all key secondary efficacy endpoints with a high degree of statistical significance.

oDemonstrated a statistically significant and clinically meaningful placebo-adjusted improvement of 8.1 points in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline at Week 6 (Cohen’s d = 0.83; p<0.0001), the study's primary endpoint.

oDemonstrated a statistically significant placebo-adjusted improvement of 7.3 points in MADRS total score from baseline at Week 12 (p<0.0001), the study’s key secondary endpoint.

oDT120 ODT was generally well tolerated, with no serious adverse events and no suicidality signal observed.

▪Completed enrollment of Phase 3 Voyage study (GAD) with 214 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo. Topline data anticipated the week of August 10, 2026.

▪Completed enrollment of Phase 3 Panorama study (GAD) with 245 participants randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo. Topline data anticipated in September 2026.

▪Initiated enrollment of Phase 3 Ascend study (MDD). The trial is expected to enroll approximately 165 participants randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo. Topline data expected in 2027.

▪Phase 3 Haven study in posttraumatic stress disorder (PTSD) is expected to initiate in 2027 and enroll approximately 200 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo. The primary endpoint in the study is expected to be the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at Week 8.

Second Quarter 2026 Financial Results

Cash, Cash Equivalents and Investments. As of June 30, 2026, Definium Therapeutics had cash, cash equivalents and investments of approximately $1.1 billion compared to $411.6 million as of December 31, 2025. Based on the Company’s current operating plan and anticipated milestones, the Company believes that its cash, cash equivalents and investments as of June 30, 2026 will be sufficient to fund the Company’s operations into 2030.

Research and Development (R&D). R&D expenses were $48.7 million for the three months ended June 30, 2026 compared to $29.8 million for the three months ended June 30, 2025, an increase of $18.9 million. The increase was primarily due to an increase of $12.9 million in expenses related to our DT120 program, an increase of $5.7 million in internal personnel costs as a result of increasing research and development capabilities, and an increase of $0.6 million in preclinical and other program expenses, partially offset by a decrease of $0.3 million in DT402 program expenses.

General and Administrative (G&A). G&A expenses were $26.4 million for the three months ended June 30, 2026, compared to $11.1 million for the three months ended June 30, 2025, an increase of $15.3 million. The increase was primarily due to an increase of $7.6 million in stock-based compensation expenses, an increase of $2.6 million in corporate and government affairs expenses, an increase of $2.0 million in personnel-related expenses, an increase of $1.8 million in commercial-preparedness related expenses, an increase of $0.6 million in legal and patent expenses, and an increase of $0.7 million in other miscellaneous administrative expenses.

2

Net loss. Net loss for the three months ended June 30, 2026 was significantly impacted by an $86.2 million non-cash increase in the fair value of warrant liabilities associated with the appreciation in the Company's share price during the period. Net loss for the three months ended June 30, 2026 was $159.0 million, compared to $42.7 million for the three months ended June 30, 2025.

Conference Call and Webcast Reminder

Definium Therapeutics management will host a webcast at 4:30 p.m. EDT today to provide a corporate update and review the Company’s second quarter 2026 financial results and business highlights. Listeners can register for the webcast via this link. The webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About DT120 Orally Disintegrating Tablet (ODT)

DT120 ODT (lysergide tartrate) is an ergoline derivative belonging to the group of classic serotonergic psychedelics which acts as a partial agonist at serotonin-2A (5-HT2A) receptors. DT120 ODT is Definium’s proprietary and pharmaceutically optimized formulation of LSD. DT120 ODT is an advanced formulation incorporating Catalent’s Zydis® ODT fast-dissolve technology, designed to deliver several unique advantages, including faster absorption and faster onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and lower incidence of gastrointestinal side effects. Definium is developing DT120, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), posttraumatic stress disorder (PTSD), and is exploring its potential applications in other serious brain health disorders. Definium maintains a strong foundation to protect and extend the long-term value of the DT120 ODT franchise through a multi-layered intellectual property strategy spanning composition, formulation, and methods-of-use patents.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit www.definiumtx.com and follow Definium Therapeutics on Instagram, LinkedIn and X.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company’s belief in DT120 ODT’s potential to become a best-in-class treatment across multiple psychiatric disorders; the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of DT120 ODT in GAD the week of August 10, 2026; the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for DT120 ODT in GAD in September 2026; the Company’s anticipated topline readout (Part A results) for the Phase 3 Ascend study for DT120 ODT in MDD in 2027; the Company’s expectations regarding enrollment for each of the Haven and Ascend studies; the Company’s expectations to initiate the Haven study in 2027; the Company’s planned trial design for Ascend and Haven; the Company’s beliefs regarding potential benefits of its product candidates; the Company’s expectation that its cash, cash equivalents and investments will fund operations into 2030; and potential additional indications for DT120 ODT. There are numerous

3

risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026 and June 30, 2026 under headings such as "Special Note Regarding Forward-Looking Statements," and "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other filings and furnishings made or to be made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.

For further information, please contact:

Investors:

Gitanjali Jain

VP, Head of Investor Relations

ir@definiumtx.com

Media:

media@definiumtx.com

4

Definium Therapeutics, Inc.

Consolidated Balance Sheets

(in thousands, except share amounts)		June 30, 2026 (unaudited)				December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$	655,267			$	257,837
Short-term investments			428,612				153,756
Prepaid and other current assets			8,222				7,727
Total current assets			1,092,101				419,320
Goodwill			19,918				19,918
Other non-current assets			880				862
Total assets		$	1,112,899			$	440,100
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable		$	6,965			$	5,347
Accrued expenses			37,222				20,446
2022 USD Financing Warrants			113,017				40,905
Total current liabilities			157,204				66,698
Credit facility, long-term			36,467				40,579
Other non-current liabilities			549				496
Total liabilities			194,220				107,773
Commitments and contingencies
Shareholders' equity:
Common shares, no par value, unlimited authorized as of June 30, 2026 and December 31, 2025; 134,365,950 and 98,776,265 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively			—				—
Additional paid-in capital			1,737,018				913,914
Accumulated other comprehensive income			417				1,085
Accumulated deficit			(818,756	)			(582,672	)
Total shareholders' equity			918,679				332,327
Total liabilities and shareholders' equity		$	1,112,899			$	440,100

5

Definium Therapeutics, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

		Three Months Ended June 30,								Six Months Ended June 30,
(in thousands, except share and per share amounts)		2026				2025				2026				2025
Operating expenses:
Research and development		$	48,665			$	29,809			$	90,149			$	53,166
General and administrative			26,412				11,094				44,148				19,896
Total operating expenses			75,077				40,903				134,297				73,062
Loss from operations			(75,077	)			(40,903	)			(134,297	)			(73,062	)
Other income/(expense):
Interest income			3,587				2,774				7,044				5,207
Interest expense			(1,233	)			(2,338	)			(2,478	)			(2,940	)
Foreign exchange loss, net			(32	)			(49	)			(76	)			(68	)
Change in fair value of 2022 USD Financing Warrants			(86,231	)			(2,228	)			(106,277	)			4,771
Total other income/(expense)			(83,909	)			(1,841	)			(101,787	)			6,970
Net loss			(158,986	)			(42,744	)			(236,084	)			(66,092	)
Other comprehensive loss
Unrealized gain/(loss) on investments			(406	)			36				(668	)			46
Loss on foreign currency translation			(1	)			(31	)			—				(58	)
Comprehensive loss		$	(159,393	)		$	(42,739	)		$	(236,752	)		$	(66,104	)
Net loss per common share, basic		$	(1.44	)		$	(0.50	)		$	(2.15	)		$	(0.78	)
Net loss per common share, diluted		$	(1.44	)		$	(0.50	)		$	(2.15	)		$	(0.81	)
Weighted-average common shares, basic			110,684,720				85,347,677				109,743,062				85,208,539
Weighted-average common shares, diluted			110,684,720				85,347,677				109,743,062				87,099,006

6

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 278.0 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.2 KB